Merkel opens Takeda’s new production facility in Germany
pharmafile | June 20, 2017 | News story | Manufacturing and Production | Germany, Takeda, merkel
Angela Merkel was part of the opening ceremony that saw Takeda announce the completion of a third production space in its Oranienburg site in Germany. Merkel took the opportunity to stress that the ties between Japan and Germany could be strengthened even further, citing the successful collaboration between the state of Brandenburg and Takeda.
The German Chancellor was keen to emphasise that the facility provided skilled jobs for the country, as well as showcasing the technological capacity of the space that utilises 3D printers for replacement parts.
The facility currently specialises in producing pills and capsules, and already supplies drugs to 100 countries worldwide, including Pantoprazole, Trintellix and Magnyl. The total investment in the site was stated to be €100 million, with the German federal government and the state of Brandenburg contributing €23 million in subsidies for the expansion.
The new expansion is projected to contribute to the overall production of the facility, which currently produced 6.2 billion tablets per year, and will be operational by the end of 2017. The new area will create 180 new jobs in the area, adding to the current number of employees of 766 at the facility.
The reason for the expansion, as stated by Takeda, is to shift production of solid dosage form pharmaceutical products from its Osaka Plant to the Oranienburgh Plant and its Hikari Plant.
“We continuously invest in our facilities to advance our technologies in order to ensure a stable supply of high-quality drug products to patients around the world,” said Thomas Wozniewski, Global Manufacturing & Supply Officer of Takeda.
Ben Hargreaves
Related Content
MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment
Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …
Takeda and ImmunoGen collaborate for development and commercialisation of Elahere in Japan
ImmunoGen has announced that it has entered into an exclusive collaboration with Takeda Pharmaceutical Company …
Takeda and HUTCHMED’s cancer drug shown to prolong overall survival
Clinical trial data from a study into the metastatic colorectal cancer (CRC) drug fruquintinib, which …
